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trix. This study opens up promising therapeutic avenues based
on gene transfer encoding selected glycosyltransferases.
On a complementary way, we have performed a structural inves-
tigation of the human recombinant GlcAT-I upon expression the
methyltrophic yeast Pichia pastoris. This study allowed to define
the molecular basis of the recognition of the donor and acceptor
substrates of the enzyme. We also determined the critical role of
the modification of the tetrasaccharidic sequence by sulfatation
of Gal residues on the regulation of the activity of GlcAT-I. Finally,
the importance of the other glycosyltransferases involved in the
construction of the tetrasaccharidic sequence is also examined.
Altogether, this study will provide the rational basis for the design
of original glycomimetics able to stimulate GAG biosynthesis in
cartilage.
Conclusions: Glycosyltransferases, especially GlcAT-I, are
promising protein targets for the development of new therapies
for osteoarthritis based on the repair of the GAG components of
cartilage.
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Purpose: Cartilage is avascular and lacks the ability to mobilize
repair cells; thus tissue damage is cumulative. Tissue engineered
cartilage repair may delay or prevent prosthetic replacement and
restore mobility. Mass transport is a major challenge in cartilage
tissue-engineering. Previous studies show that mesenchymal
stem cell (MSC)-based constructs develop a shell of differenti-
ated material surrounding a viable but undifferentiated core. This
suggests that a) penetration of one or more substrates required
for differentiation is limited, or b) more generally, that the differen-
tiation process transiently increases the metabolic requirements
of the cells. The purpose of this study is to understand the na-
ture and time course of the mass transport limitations during the
maturation of tissue engineered constructs.
Methods: We combined in vitro and in silico approaches to un-
derstand the metabolic needs of the cells during chondrogenic
differentiation. Constructs were made from 107 1st passage hu-
man MSCs that were seeded onto collagen-GAG porous scaf-
folds and exposed to a chondrogenic medium in a custom-built
bioreactor. We assessed mass transport within the construct us-
ing dextran tracers of 3, 10 and 70 kDa MW at various time-points
during differentiation. We modelled momentum and mass trans-
port using a finite element analysis software package. A detailed
3-dimensional geometric rendering, Fickian diffusion and Navier-
Stokes equations and Michaelis-Menten oxygen consumption
kinetics were used in the model. Consumption rate estimates
were obtained either from the existing literature or were com-
puted from measurements made using a purpose-built oxygen
consumption cell.
Results: We created a 3-dimensional computer model of our
custom-built bioreactor system and the growing cartilage con-
struct. Diffusion experiments, using image analysis data fitted
to a diffusion model, were used to derive estimates of diffusivi-
ties of 3, 10, and 70 kDa molecular weight fluorescent dextran
tracers through the constructs. The estimated diffusivities in the
constructs were 2-3 orders of magnitude lower than that in water
(0.3-2 vs. 50-240 μm2/sec). The diffusivities also depended on
the molecular weight of the tracer and on the maturity of the
construct; two-week old constructs had the lowest diffusivities.
Mass transport modelling carried out using experimentally de-
termined diffusivities shows that large chondrogenic molecules,
such as TGF-β1, do not reach useful concentrations in the in-
terior of the construct even over a week. In parallel, the initially
high oxygen needs of MSCs decrease during their differentiation
to chondrocytes.
Conclusions: We have developed a model that defines mass
transport through the construct under a variety of culture con-
ditions and will predict the effects of design modifications to
the bioreactor system. Modelling results suggest a limiting role
for substrate mass transport in large-scale cartilage implants.
Specifically, large signalling molecules diffuse slowly into the
constructs resulting in an undifferentiated cartilage shell. Fu-
ture studies will define the dynamics of cell differentiation, and
nutrient-dependent cell division/death. These strategies will ulti-
mately lead to the development of clinically useful tissue engi-
neered cartilage constructs.
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Purpose: Common strategies in the treatment of OA do not
address most of the underlying pathomechanisms. Several bi-
ologically based, local therapies are either in clinical use or in
development. A new therapy based on the intra-articular injec-
tion of autologous conditioned serum (ACS) has shown clinical
benefits in animal and human studies.In the present study, the
clinical efficacy and safety of intra-articular injections of ACS
were compared to intra-articular hyaluronan (HA) and saline in
patients with confirmed knee OA.
Methods: ACS is generated by incubating venous blood with
medical grade glass beads. Peripheral blood leukocytes produce
elevated amounts of endogenous anti-inflammatory cytokines,
such as interleukin-1 receptor antagonist (IL-1Ra), that are re-
covered in the serum(1).
In a prospective, randomized, patient- and observer-blind, saline-
controlled trial with three parallel groups, 399 patients with knee
OA were included with the intention to treat (ITT-) analysis.
Efficacy was assessed by patient-administered outcome instru-
ments (WOMAC, VAS, SF-8, GPA) after 7, 13 and 26 weeks. The
frequency and severity of adverse events were used as safety
parameters.
Results: In all treatment groups, intra-articular injections pro-
duced a significant reduction in WOMAC-scores and weight-
bearing pain (VAS), as well as an improvement in the health-
related quality of life. However, the positive therapeutic responses
to ACS were stronger compared to other treatment modalities.
The superiority of ACS to both HA and saline was statistically sig-
nificant for all outcome measures and all time points. The mean
improvement for patients treated with HA and saline was half
that than in the ACS-group (p<0.001). No significant differences
between HA treatment and saline-injections (p>0,05, at all time
points and all outcome measures) were recorded. Frequency of
adverse advents (AE) was comparable in the ACS- and saline-
group (p>0,05), whereas there were significantly more AE in the
HA-group (p<0,05 for the comparison with ACS and saline).
Conclusions: Patients with OA of the knee treated with intra-
articular injections of ACS showed significantly better clinical
improvement during 26 weeks of observation compared to pa-
tients injected with HA or saline. The results demonstrate that
ACS is effective and well tolerated for treating chronic, idiopathic
OA of the knee. So far, the efficacy of ACS is defined through
improvement in clinical signs and symptoms, particularly pain. It
remains to be determined whether there are disease-modifying,
chondroprotective, or even chondroregenerative, sequelae.
